tiprankstipranks
NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
PremiumPress ReleasesNeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
2M ago
NeuroBo Pharmaceuticals announces upcoming anticipated milestones
PremiumThe Fly
NeuroBo Pharmaceuticals announces upcoming anticipated milestones
2M ago
NeuroBo Pharmaceuticals reports Q1 EPS ($1.32) vs (51c) last year
PremiumThe Fly
NeuroBo Pharmaceuticals reports Q1 EPS ($1.32) vs (51c) last year
2M ago
NeuroBo Pharmaceuticals management to meet with Maxim Group
PremiumThe FlyNeuroBo Pharmaceuticals management to meet with Maxim Group
2M ago
NeuroBo Pharmaceuticals management to meet with Maxim Group
PremiumThe Fly
NeuroBo Pharmaceuticals management to meet with Maxim Group
2M ago
NeuroBo Pharmaceuticals doses first patient in Phase 1 DA-1726 trial
PremiumThe Fly
NeuroBo Pharmaceuticals doses first patient in Phase 1 DA-1726 trial
3M ago
NeuroBo Pharmaceuticals Announces Key Leadership Appointment
PremiumCompany AnnouncementsNeuroBo Pharmaceuticals Announces Key Leadership Appointment
4M ago
NeuroBo Pharmaceuticals receives first site IRB approval for obesity trial
PremiumThe Fly
NeuroBo Pharmaceuticals receives first site IRB approval for obesity trial
4M ago
NeuroBo Pharmaceuticals Signals Updates in Corporate Outlook
PremiumCompany Announcements
NeuroBo Pharmaceuticals Signals Updates in Corporate Outlook
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100